Citation tools
"Peptide Receptor Radionuclide Therapy or Everolimus in Metastatic Neuroendocrine Tumors: The SeqEveRIV Study, a National Study from the French Group of Endocrine Tumors and Endocan–RENATEN Network." Journal of Nuclear Medicine
65.9
(2024):
1416-1422.
Web. 02 May. 2025.